1,688
Views
11
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: RADIOTHERAPY

Long-term outcomes following stereotactic body radiotherapy boost for oropharyngeal squamous cell carcinoma

, , , , , , & ORCID Icon show all
Pages 926-933 | Received 28 Nov 2018, Accepted 05 Feb 2019, Published online: 27 Feb 2019

Figures & data

Table 1. Baseline characteristics of the study population (n = 195).

Figure 1. Kaplan-Meier plots showing freedom from locoregional progression, freedom from any progression, disease-specific survival, overall survival, and disease-free survival.

Figure 1. Kaplan-Meier plots showing freedom from locoregional progression, freedom from any progression, disease-specific survival, overall survival, and disease-free survival.

Figure 2. Kaplan-Meier plots showing cumulative incidence of late grade ≥3 toxicity in 182 patients.

Figure 2. Kaplan-Meier plots showing cumulative incidence of late grade ≥3 toxicity in 182 patients.

Figure 3. Kaplan-Meier plots showing cumulative incidence of specific late grade ≥3 toxicity in 182 patients.

Figure 3. Kaplan-Meier plots showing cumulative incidence of specific late grade ≥3 toxicity in 182 patients.

Table 2. Distribution of maximum toxicity scores in 182 evaluated patients (crude numbers).

Table 3. Prognostic factors for grade ≥3 late toxicity.

Supplemental material

Supplemental Material

Download Zip (91.9 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.